JP5086331B2 - 細菌性疾患、ウィルス性疾患、真菌症、炎症、及び疼痛の治療用組成物 - Google Patents
細菌性疾患、ウィルス性疾患、真菌症、炎症、及び疼痛の治療用組成物 Download PDFInfo
- Publication number
- JP5086331B2 JP5086331B2 JP2009501394A JP2009501394A JP5086331B2 JP 5086331 B2 JP5086331 B2 JP 5086331B2 JP 2009501394 A JP2009501394 A JP 2009501394A JP 2009501394 A JP2009501394 A JP 2009501394A JP 5086331 B2 JP5086331 B2 JP 5086331B2
- Authority
- JP
- Japan
- Prior art keywords
- organic solvent
- water
- pain
- immiscible organic
- solvent extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 49
- 230000036407 pain Effects 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 208000035143 Bacterial infection Diseases 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 title claims description 8
- 230000004054 inflammatory process Effects 0.000 title abstract description 22
- 206010061218 Inflammation Diseases 0.000 title abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 18
- 230000003612 virological effect Effects 0.000 title abstract description 6
- 201000010099 disease Diseases 0.000 title description 13
- 206010017533 Fungal infection Diseases 0.000 title description 7
- 208000024386 fungal infectious disease Diseases 0.000 title description 2
- 239000003960 organic solvent Substances 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 18
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930182817 methionine Natural products 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004452 methionine Drugs 0.000 claims description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002480 mineral oil Substances 0.000 claims description 7
- 235000010446 mineral oil Nutrition 0.000 claims description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 5
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229930182818 D-methionine Natural products 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 1
- 125000000296 D-methionine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])SC([H])([H])[H] 0.000 claims 1
- 208000012285 hip pain Diseases 0.000 claims 1
- 208000024765 knee pain Diseases 0.000 claims 1
- 230000008833 sun damage Effects 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 abstract description 7
- 208000035475 disorder Diseases 0.000 abstract description 5
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 235000006109 methionine Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 230000006378 damage Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010068106 Occipital neuralgia Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003461 brachial plexus Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010066371 Tendon pain Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229940124642 endogenous agent Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- -1 sodium hypochlorite Chemical compound 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Agronomy & Crop Science (AREA)
- Inorganic Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Dentistry (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(a)メチオニンを水と混和し、
(b)メチオニン溶液に次亜塩素酸塩溶液を加え、0℃〜室温の温度で混和し、
(c)上記(b)に水不混和性有機溶媒を加えて混和し、そして
(d)有機溶媒相を水相から分離して有機溶媒抽出物を得る
を含む方法で調製される。
他の1つの実施形態において、本発明はインフルエンザ感染などのウィルス性疾患を治療する方法を提供する。
他の1つの実施形態において、本発明は真菌感染、例えば汗疱状白癬、イースト菌感染症、副鼻腔感染症等の真菌病を治療する方法を提供する。
他の1つの実施形態において、本発明は火傷又は太陽による皮膚の損傷、皮膚のしみ、又は疣などの皮膚の状態を治療する方法を提供する。
他の1つの実施形態において、本発明は炎症又は炎症関連障害を治療する方法を提供する。本発明は、疼痛、腫脹、体温上昇、又は場合によっては機能喪失などの炎症又は炎症関連障害を軽減する。
ブレンダー中において、0〜4℃の蒸留水720〜750mlと20gのDLメチオニンの細末(Degussa Corp., Richfield Park, NJ)を合わせ、アルゴン下で数秒間混和した。メチオニン固体が蒸留水中に一様に懸濁された後、0〜4℃のClorox漂白剤(6%の次亜塩素酸ナトリウム)370〜400mlを加え、アルゴン下で30秒間混合速度で混和した。溶液が透明になり、そして泡が上部に形成されるまで、30秒から1分間反応物を静置した。泡は過剰のメチオニンであり、そして場合により取り除かれた。
水-油混合物を、3〜4時間静置し、そして次にオイル相を取り出し、20μmの濾紙を通して濾過した。濾液を開放容器の中で3日間貯蔵して、アルゴンを消散させ、そして油性濾液は、生成物として使用する準備ができた。
実施例1の生成物の肝毒性についての生体内評価をラット集合で行った。
10匹のラットからなる対照群を、ベースラインの血清酵素及び病理組織学の対照解析のために処理を行なわなかった。
10匹のラットからなる第2群を、標準生理食塩水で1日2回給餌して、繰り返し使用とチューブかん強制飼養についての効果を評価した。
25匹のラットからなる第3群には、1日2回、ミネラルオイルのみを強制飼養した。
25匹のラットからなる第4群には、1日2回、実施例1の生成物を強制飼養した。
28日後に、ラットを麻酔し、そして、標準方法論に従って肝臓を検査した。実施例1の生成物の接取は肝毒性の徴候をもたらさなかったと結論された。
実施例1の生成物は種々の感染症を示した対象を治療するために使われた。結果を表1に要約する。
関節痛、虫刺され、火傷疼痛を有する対照が、実施例1の生成物で治療された。結果を表2に要約する。
表3に示されるように、実施例1の生成物は、火傷、または皮膚の状態に問題のある者に1日3回局所的に適用された。生成物の適用の後に、被検者の徴候は軽減した。
Claims (10)
- 以下のステップ:
(a) メチオニンを水と混和し、
(b) 上記(a)に次亜塩素酸塩水溶液を加え、0℃〜室温の温度で混和し、
(c) 上記(b)に水不混和性有機溶媒を加え、そして混和し、ここで当該水不混和性有機溶媒がヘキサン、ヘプタン、塩化メチレン、ミネラルオイル、植物油、又は酢酸エチルであり、そして
(d) 上記有機溶媒相を分離する
を含む方法により調製された水不混和性有機溶媒抽出物。 - 工程(c)が、工程(b)の後5分以内に行われる、請求項1に記載の水不混和性有機溶媒抽出物。
- 前記水不混和性有機溶媒が、ミネラルオイル又はヘキサンである請求項2に記載の水不混和性有機溶媒抽出物。
- 前記ステップ(a)と(b)が、不活性ガスのもとで行われる、請求項1に記載の水不混和性有機溶媒抽出物。
- 前記メチオニンが、D-メチオニン、L-メチオニン、又はその混合物である、請求項1に記載の水不混和性有機溶媒抽出物。
- 前記抽出物が、疼痛緩和作用、細菌感染治療作用、及び皮膚状態改善作用を有する、請求項1〜5のいずれか一項に記載の水不混和性有機溶媒抽出物。
- 請求項1に記載の水不混和性有機溶媒抽出物を含む、対象においてブドウ球菌感染を治療するための医薬組成物。
- 対象において疼痛治療用の医薬組成物であって、請求項1に記載の水不混和性有機溶媒抽出物を含み、ここで当該疼痛が股関節痛、関節炎痛、背痛、膝痛、筋肉痛又は火傷痛である、前記医薬組成物。
- 対象において皮膚状態治療用の医薬組成物であって、請求項1に記載の水不混和性有機溶媒抽出物を含み、ここで当該皮膚状態が、火傷、日焼けによる皮膚損傷、皮膚のシミ又はいぼである、前記医薬組成物。
- 疼痛緩和作用、細菌感染治療作用、及び皮膚状態改善作用を有する水不混和性有機溶媒抽出物の製造方法であって、以下のステップ:
(a) メチオニンを水と混和し、
(b) 上記(a)に次亜塩素酸塩水溶液を加え、0℃〜室温の温度で混和し、
(c) 上記(b)に水不混和性有機溶媒を加え、そして混和し、ここで当該水不混和性有機溶媒がヘキサン、ヘプタン、塩化メチレン、ミネラルオイル、植物油、又は酢酸エチルであり、そして
(d) 上記有機溶媒相を分離する
を含む、前記方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/010665 WO2007108807A1 (en) | 2006-03-20 | 2006-03-20 | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009534305A JP2009534305A (ja) | 2009-09-24 |
JP5086331B2 true JP5086331B2 (ja) | 2012-11-28 |
Family
ID=38522752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009501394A Expired - Fee Related JP5086331B2 (ja) | 2006-03-20 | 2006-03-20 | 細菌性疾患、ウィルス性疾患、真菌症、炎症、及び疼痛の治療用組成物 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1996014B1 (ja) |
JP (1) | JP5086331B2 (ja) |
CN (1) | CN101400255B (ja) |
AT (1) | ATE488137T1 (ja) |
AU (1) | AU2006340367B2 (ja) |
BR (1) | BRPI0621416A2 (ja) |
CA (1) | CA2645881A1 (ja) |
DE (1) | DE602006018367D1 (ja) |
MX (1) | MX2008011934A (ja) |
WO (1) | WO2007108807A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2520034C2 (ru) * | 2009-03-18 | 2014-06-20 | ОЛАТЕК ИНДАСТРИЗ ЭлЭлСи | Соединения для лечения воспаления |
WO2012082718A2 (en) | 2010-12-15 | 2012-06-21 | Olatec Industries Llc | 3-methanesulfonylpropionitrile for treating inflammation and pain |
KR102112883B1 (ko) * | 2012-06-05 | 2020-05-19 | 오라텍 세라퓨틱스 엘엘씨 | 피부 염증 질환의 치료 방법 |
CN109453194A (zh) * | 2018-11-21 | 2019-03-12 | 四川水喜宝科技发展有限公司 | 一种物理灭菌活化养目的中药组合物及组合套装 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2106389B (en) * | 1981-07-16 | 1985-07-17 | Nat Res Dev | The inhibition of growth in fungi |
US5053429A (en) * | 1988-04-08 | 1991-10-01 | The Lithox Corporation, Inc. | Treating inflammatory pain with methionine |
US5084482A (en) * | 1990-04-10 | 1992-01-28 | The Lithox Corporation | Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds |
AU2003295579A1 (en) * | 2002-11-15 | 2004-06-15 | Regents Of The University Of California | Anti-microbial agents derived from methionine sulfoximine analogues |
-
2006
- 2006-03-20 MX MX2008011934A patent/MX2008011934A/es not_active Application Discontinuation
- 2006-03-20 CN CN2006800539294A patent/CN101400255B/zh not_active Expired - Fee Related
- 2006-03-20 JP JP2009501394A patent/JP5086331B2/ja not_active Expired - Fee Related
- 2006-03-20 WO PCT/US2006/010665 patent/WO2007108807A1/en active Application Filing
- 2006-03-20 AU AU2006340367A patent/AU2006340367B2/en not_active Ceased
- 2006-03-20 AT AT06739456T patent/ATE488137T1/de not_active IP Right Cessation
- 2006-03-20 BR BRPI0621416-9A patent/BRPI0621416A2/pt not_active Application Discontinuation
- 2006-03-20 DE DE602006018367T patent/DE602006018367D1/de active Active
- 2006-03-20 CA CA002645881A patent/CA2645881A1/en not_active Abandoned
- 2006-03-20 EP EP06739456A patent/EP1996014B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP1996014A1 (en) | 2008-12-03 |
AU2006340367A1 (en) | 2007-09-27 |
MX2008011934A (es) | 2008-11-27 |
ATE488137T1 (de) | 2010-12-15 |
JP2009534305A (ja) | 2009-09-24 |
EP1996014B1 (en) | 2010-11-17 |
CN101400255A (zh) | 2009-04-01 |
CN101400255B (zh) | 2012-07-04 |
BRPI0621416A2 (pt) | 2011-12-06 |
WO2007108807A1 (en) | 2007-09-27 |
AU2006340367B2 (en) | 2012-12-20 |
CA2645881A1 (en) | 2007-09-27 |
EP1996014A4 (en) | 2009-11-11 |
DE602006018367D1 (de) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8003696B2 (en) | Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain | |
SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
CN113274342B (zh) | 一种秋水仙碱外用组合物 | |
JP5086331B2 (ja) | 細菌性疾患、ウィルス性疾患、真菌症、炎症、及び疼痛の治療用組成物 | |
CN106389392A (zh) | 一种他达拉非口腔溶膜剂及制备方法 | |
CN105078909B (zh) | 一种注射用苯磺顺阿曲库铵冷冻干燥组合物及其制备方法 | |
WO2021099453A1 (fr) | Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes | |
JP7190571B2 (ja) | ブレイアコニチンaの用途 | |
WO2017088177A1 (zh) | 贻贝粘蛋白产品及其预防和抑制神经炎症的应用 | |
CN103638060A (zh) | 侧狭腹胡蜂属昆虫蜂毒多肽有效部位及其制备和医药用途 | |
RU2403035C2 (ru) | Композиция для лечения бактериальных, вирусных, грибковых заболеваний, воспаления и боли | |
JP3253878B2 (ja) | 鉄キレート化用製剤、その製剤の製法及び地中海貧血症の治療法 | |
EP1967187B1 (fr) | Composition à base de rutine et de L-lysine | |
RU2340372C2 (ru) | Способ лечения туберкулеза легких | |
KR20080108994A (ko) | 세균성, 바이러스성, 진균성 질환, 염증 및 통증의 치료를 위한 조성물 | |
JP2008542369A (ja) | Avr118を用いて苦痛緩和医療を提供する方法 | |
JP2002173434A (ja) | 抗アレルギー性組成物 | |
RU2122418C1 (ru) | Средство для лечения хронического гепатита неинфекционной этиологии | |
RU2212235C1 (ru) | Капли назальные бризолин, обладающие сосудосуживающим, противовоспалительным и противоотечным действием | |
RU2561593C1 (ru) | Комбинированное аппликационное лекарственное фитосредство | |
JP2002145791A (ja) | 抗炎症性組成物 | |
RU2107503C1 (ru) | Средство для обезболивания | |
CN103655632A (zh) | 马蜂科昆虫蜂毒多肽有效部位的及其制备方法和用途 | |
JP2021070661A (ja) | Tslp遺伝子発現抑制用、il−33遺伝子発現抑制用、又はフィラグリン産生促進用組成物 | |
JP2004143105A (ja) | ニンジン主薬保健剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120807 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120906 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5086331 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |